Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Period	Net Profit Margin
2022-12-31	N/A
2023-12-31	N/A
2024-12-31	-60.03%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CNTB	$2.66	-5.67%	0.37M
3
4
5

Connect Biopharma Holdings Limited (CNTB) Profit Margin

Profit Margin Data

Get Connect Biopharma Holdings Limited Data in Excel

More CNTB Financial Data